GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Net Margin %

Enlivex Therapeutics (Enlivex Therapeutics) Net Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Enlivex Therapeutics's Net Income for the three months ended in Sep. 2023 was $-5.96 Mil. Enlivex Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Enlivex Therapeutics's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Enlivex Therapeutics's Net Margin % or its related term are showing as below:


ENLV's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -160.92
* Ranked among companies with meaningful Net Margin % only.

Enlivex Therapeutics Net Margin % Historical Data

The historical data trend for Enlivex Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Net Margin % Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enlivex Therapeutics's Net Margin %

For the Biotechnology subindustry, Enlivex Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Net Margin % falls into.



Enlivex Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Enlivex Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-31.06/0
= %

Enlivex Therapeutics's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-5.963/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enlivex Therapeutics  (NAS:ENLV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Enlivex Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus

Enlivex Appoints Andrew Singer to its Board of Directors

By sperokesalga sperokesalga 04-17-2023